Dapsone Therapy: Indications, Dosing, Monitoring, and Contraindications
FDA-Approved Indications
Dapsone is FDA-approved for three conditions: leprosy, dermatitis herpetiformis, and acne vulgaris (topical formulation), with specific dosing protocols that must be followed for each indication 1.
Dermatitis Herpetiformis
- Start at 50 mg daily in adults (proportionally lower in children)
- Titrate up to 50-300 mg daily based on response
- Higher doses may be tried if control is inadequate within this range
- Reduce to minimum maintenance dose as soon as possible
- Expect prompt reduction in pruritus followed by skin lesion clearance
- A strict gluten-free diet can reduce or eliminate dapsone need (average 8 months for dose reduction, 29 months for elimination) 1
Leprosy
Dapsone must be used in combination with other anti-leprosy drugs to prevent secondary resistance 1:
For tuberculoid/indeterminate disease:
- Dapsone 100 mg daily + Rifampin 600 mg daily for 6 months
- Continue dapsone until clinical activity controlled (usually additional 6 months)
- Then continue dapsone for 3 more years (tuberculoid/indeterminate) or 5 years (borderline tuberculoid)
For lepromatous/borderline lepromatous disease:
- Dapsone 100 mg daily + Rifampin 600 mg daily for 2 years
- Consider adding third agent (Clofazimine 50-100 mg daily or Ethionamide 250-500 mg daily)
- Continue dapsone 3-10 years until clinically inactive with negative biopsies for 1 year
- Then continue dapsone for 10 more years (borderline) or lifelong (lepromatous) 1
Off-Label Uses
Dapsone has extensive off-label applications in dermatology including bullous pemphigoid, Behçet's disease, lupus erythematosus, and various inflammatory conditions 2, 3. For HIV-related prophylaxis, dapsone 100 mg daily can be used for PCP prevention, though trimethoprim-sulfamethoxazole remains preferred 4.
Critical Monitoring Parameters
Before initiating dapsone, obtain baseline laboratory tests including complete blood count, liver function tests, and G6PD screening 5. The most serious adverse effects include:
- Hemolytic anemia (dose-related, occurs in all patients to some degree)
- Methemoglobinemia (dose-related)
- Agranulocytosis (rare but potentially fatal)
- Dapsone hypersensitivity syndrome (fever, rash, hepatitis - typically weeks 2-6)
Monitor CBC and liver function tests at 2 weeks, 4 weeks, then monthly for 6 months, then every 6 months thereafter 5. A risk-management program implementing these monitoring parameters improved adherence from 61.4% to 95.3% and prevented severe adverse effects 5.
Contraindications and Precautions
Absolute contraindications:
- Severe G6PD deficiency (high risk of life-threatening hemolysis)
- Known hypersensitivity to dapsone or sulfonamides
Relative contraindications/use with caution:
- Mild-moderate G6PD deficiency (dose adjustment may be needed)
- Severe anemia
- Hepatic impairment
- Renal impairment
- Concurrent medications affecting acetylation (may require dose adjustment) 1
Pharmacokinetic Considerations
Dapsone levels are influenced by acetylation rates - patients with high acetylation rates or receiving medications affecting acetylation may require dose adjustments 1. The drug has anti-inflammatory properties including inhibition of reactive oxygen species production and down-regulation of neutrophil-mediated inflammatory responses, which explains its efficacy beyond antimicrobial effects 3.
Common Pitfalls to Avoid
- Never use dapsone monotherapy for leprosy - this promotes resistance 1
- Do not skip G6PD testing - hemolysis can be catastrophic in deficient patients
- Watch for dapsone hypersensitivity syndrome in weeks 2-6 - requires immediate discontinuation
- Suspect dapsone resistance in leprosy patients who relapse clinically and bacteriologically despite regular supervised therapy for 3-6 months 1
- Ensure adequate follow-up monitoring - the majority of severe adverse effects are preventable with proper surveillance 5